dsm-firmenich, an ingredients specialist in the nutrition, health and beauty sectors, has launched CBtru, an advanced cannabidiol (CBD) drug product intermediate for oral solid delivery.
The CBD intermediate allows for a higher drug loading compared to those currently on the market, enhancing bioavailability and efficacy of supplements containing the functional ingredient.
The ingredient will also enable the development of CBD supplements in a convenient and popular dosage form, such as orally disintegrating tablets or chewables.
Enhanced bioavailability and efficacy
CBD-based medicines currently on the market exhibit limited oral bioavailability and efficacy due to their poor solubility and cannabinoid molecule absorption.1
Consequently, large doses are necessary to get any of CBD's associated benefits, and often require administration via oil-based oral solutions — which can be an unpleasant experience for patients to ingest.
dsm's formulated CBD drug product intermedia aims to address this challenge by allowing higher active loading, improved stability and optimised pharmacokinetic performance — enabling the creation of more bioavailable and patient-friendly dosage forms.
“We invested in CBD due to its immense therapeutic potential, as evidenced by promising research and a shifting favorable regulatory environment,” remarks Global Business Development Manager for Pharma at dsm-firmenich, Athanasia Kanli. “To date, the application of CBD has been limited to oil-based delivery systems though, principally because of its low bioavailability and physical and chemical instability. This inspired us to introduce CBtru. With its advanced functionality, CBtru can facilitate the development of faster-acting, more effective and patient-friendly treatments – representing a new era in cannabinoid-based medicines.”
